ReviewFrontiers in surgery2026
Breast cancer-related lymphedema of the upper limb: integrating early surveillance and functional surgery into a synergistic management paradigm.
Review in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer-related lymphedema (BCRL) of the upper limb is a chronic complication of breast cancer treatment that significantly impairs patient quality of life. Conventional management typically begins only after overt swelling occurs. This reactive approach delays diagnosis, relies on subjective assessment, and prioritizes volume reduction over functional recovery. Consequently, it often misses the optimal window for intervention. Recent advances in objective early-monitoring technologies, such as hyperspectral imaging and bioelectrical impedance analysis, alongside the development of precision functional lymphatic surgery, are now transforming BCRL care. This article details a novel "Precision Collaborative Management" paradigm, which integrates these diagnostic and surgical advances into a synergistic cycle where monitoring informs clinical decisions and surgical outcomes refine subsequent strategies. This paradigm establishes a continuous management pathway encompassing risk screening, early warning, precise intervention, and long-term follow-up across the entire disease continuum. Through sustained exploration in the aforementioned directions, we aim to transform BCRL management from a reactive symptom treatment to a proactive health safeguard, ultimately empowering breast cancer survivors to achieve a comprehensive and high-quality life. The paradigm facilitates a fundamental shift in BCRL clinical practice from delayed symptomatic treatment to early, function-preserving care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.